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Abstract: Although prostate cancer control using radiotherapy is dose-dependent,
dose–volume effects on late toxicities in organs at risk, such as the rectum and bladder,
have been observed. Both protons and carbon ions offer advantageous physical
properties for radiotherapy, and create favorable dose distributions using fewer portals
compared with photon-based radiotherapy. Thus, particle beam therapy using protons
and carbon ions theoretically seems suitable for dose escalation and reduced risk of
toxicity. However, it is difficult to evaluate the superiority of particle beam radiotherapy
over photon beam radiotherapy for prostate cancer, as no clinical trials have directly
compared the outcomes between the two types of therapy due to the limited number of
facilities using particle beam therapy. The Japanese Society for Radiation Oncology
organized a joint effort among research groups to establish standardized treatment
policies and indications for particle beam therapy according to disease, and multicenter
prospective studies have been planned for several common cancers. Clinical trials of
proton beam therapy for intermediate-risk prostate cancer and carbon-ion therapy for
high-risk prostate cancer have already begun. As particle beam therapy for prostate
cancer is covered by the Japanese national health insurance system as of April 2018,
and the number of facilities practicing particle beam therapy has increased recently, the
number of prostate cancer patients treated with particle beam therapy in Japan is
expected to increase drastically. Here, we review the results from studies of particle
beam therapy for prostate cancer and discuss future developments in this field.
Key words: biochemical relapse-free survival, carbon-ion radiotherapy, prostate cancer,
proton beam therapy, toxicity.
Background of external beam RT for prostate cancer
Approximately 165 000 people develop prostate cancer per year in the USA, with 29 000
prostate cancer-related deaths per year.1 In Japan, the annual number of newly diagnosed
patients increases every year, and prostate cancer is currently the cause of death of >12 000
patients.2 As recent advances in prostate cancer screening and treatment have led to an
improvement in patient outcomes, the treatment goals have changed from merely tumor con-
trol to preservation of the daily activities and QOL of patients as important end-points in
comparisons of the various treatment options. In particular, it is important that treatment is as
minimally invasive as possible for elderly patients.
According to recent large-scale comparative studies evaluating several end-points, such as
prostate cancer-speciﬁc mortality rate, disease progression, metastasis and all-cause mortality
rate, external beam RT produces outcomes comparable with those of surgery; RT has thus
been established as a curative treatment for prostate cancer.3 Reports have shown that as the
radiation dose used for prostate cancer is increased, a dose–response relationship is observed
between the RT dose and tumor control.4,5 Conversely, increasing the RT dose leads to con-
cerns about adverse events in the rectum and bladder, and decreasing the RT dose and
© 2019 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. 971
International Journal of Urology (2019) 26, 971--979 doi: 10.1111/iju.14041
volume in these organs decreases the incidence of adverse
events, according to several studies that carried out dose–vol-
ume histogram analyses.6–8 Thus, if the RT dose to the pros-
tate can be increased without increasing the irradiated volume
in the rectum and bladder, treatment outcomes will improve.
With X-ray-based RT regimens, a dose build-up effect
occurs 1–2 cm from the body surface. After delivery of the
peak dose, the deeper the rays penetrate into the body, the
more gradual the decrease in the relative dose as the rays
pass through the body. In contrast, charged particle beams
differ from photon beams in that they create a better dose
distribution in the target volume by speciﬁc beam modula-
tions, such as a SOBP (Fig. 1).9–11 Thus, the prescribed dose
can be delivered to the lesion through a smaller number of
beams with particle beam RT compared with photon beam
RT, and consequently the irradiated volume and dose in the
rectum and bladder in particle beam RT for prostate cancer
can be decreased compared with photon beam RT, such as
IMRT and volumetric-modulated arc therapy (Fig. 2).12 One
reason why particle beam RT is useful for treating prostate
cancer is that dose escalation using modern techniques has
improved tumor control rates, especially bRF or bRFS rates,
in photon beam RT series, and charged particles might be
even more useful for safely escalating the RT dose.13–15
In this article, we review the results of previous particle
beam RT studies compared with photon beam RT, and intro-
duce ongoing studies and future prospects to establish high-
quality evidence for particle beam RT for prostate cancer.
Scientific statements
Concomitant photon and proton beam RT:
1990s to early 2000s
The treatment outcomes of four randomized comparative trials
carried out in the 1990s (two photon beam RT studies and two
studies on combination of PBT with photon beam RT) and a
PBT study carried out at Loma Linda University are shown in
Table 1.6,16–19 At that time, the appropriate use of ADT com-
bined with RT for prostate cancer was not yet established, and
pelvic RT using photons was a standard treatment for latent
lymph node involvement. PBT was therefore used as a RT
boost to the prostate after pelvic RT. Shipley et al.14 reported
the results from the ﬁrst randomized PBT study carried out at
Massachusetts General Hospital Cancer Center. In their study,
patients in the standard-dose group were treated with pelvic
RT at 50.4 Gy/28 fr, followed by local photon beam RT at
16.8 Gy/8 fr (total dose 67.2 Gy/36 fr), and those in the high-
dose group were treated with PBT at 25.2 GyE/12 fr together
with pelvic RT (total dose 75.6 GyE/40 fr). Good local control
was achieved in the high-dose PBT group, in which the 8-year
local control rate was 73% compared with 59% in the stan-
dard-dose photon beam RT group.14 Especially among the
patients with poorly differentiated adenocarcinoma, the rate in
the high-dose group was signiﬁcantly better (84% vs 19%,
P = 0.0014). Furthermore, grade 3 rectal bleeding was seen in
just 2.9% of the patients in the high-dose group. In contrast,
the Radiation Therapy Oncology Group carried out a random-
ized trial using photon beam RT (RTOG9413), designed as a
2 9 2 factorial study using ADT sequencing as one stratiﬁca-
tion factor and the radiation ﬁeld as the other factor. In a sec-
ondary analysis, pelvic RT combined with neoadjuvant ADT
was added for disease control of patients who had an estimated
risk of lymph node involvement of >15%, according to the
equation: percentages of positive lymph nodes = (2/3)
PSA + [(GS  6) 9 10] or T2c–T4 diseases, and showed an
improvement in PFS compared with prostate-only RT; how-
ever, despite using a 70.2 Gy dose (5.4 Gy lower than the
aforementioned 75.6 Gy PBT dose), grade 3 GI toxicities were
noted in 4.3% of patients15 (Table 1).
The effect of a high-dose PBT boost after local photon
beam RT on the outcomes of patients with stage T1–2 pros-
tate cancer was evaluated in the PROG95-09 trial.16 A PBT
boost of either 19.8 GyE/11 fr (standard-dose group) or
28.8 GyE/16 fr (high-dose group) was delivered to the pros-
tate at a total dose of 50.4 Gy/28 fr after conformal photon
beam RT. After a median observation period of 8.9 years, the
10-year biochemical failure rates were 32.4% in the standard-
dose group and 16.7% in the high-dose group (P < 0.0001),
but grade 3 GI and GU events were only noted in 1% and
2% of patients in the high-dose group, respectively. At
almost the same time, long-term results from a randomized
dose-escalation trial of photon beam RT for prostate cancer
carried out at the MD Anderson Cancer Center were
reported.6 In that study, the treatment outcomes of the stan-
dard-dose (70 Gy/35 fr) group and high-dose (78 Gy/39 fr)
group were compared (Table 1). The 10-year recurrence-free
rate was 50% in the standard-dose group versus 73% in the
high-dose group, showing that the higher dose produced bet-
ter results (P = 0.004). However, grade 3 GI and GU adverse
events were observed in 7% and 5% of patients, respectively,
in the high-dose group, indicating higher adverse event rates
compared with those induced by the 79.2 GyE dose of the
high-dose group in the ROG95-09 trial described above
(Table 1).6
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Fig. 1 A schema of relative doses from the skin surface of photon and par-
ticle beams. Dashed black and solid pink lines are the depth dose distribu-
tions of proton and carbon-ion beams, respectively. The SOBP are created
by adding the contributions of some pristine Bragg peaks. A depth dose
curve of a photon beam is provided for comparison.
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In Japan, to conﬁrm the safety of localized PBT, phase II
clinical studies were carried out at the National Cancer Cen-
ter Hospital East, in which 30 patients were registered over
2 years starting in 2001. Photon beam RT consisting of
50 Gy/25 fr was delivered to the prostate and bilateral semi-
nal vesicles, followed by a PBT boost of 26 GyE/13 fr to the
prostate alone. No grade 3 acute or late toxicities were
observed, conﬁrming the feasibility of high-dose RT with a
PBT boost for prostate cancer.18
Local particle beam RT: Mainly in the 2000s
At Loma Linda University, high-dose PBT without photons
was used to treat localized prostate cancer. Between 1991
and 1997, 911 cases were treated with localized PBT at a
total dose of 74–75 Gy, and a 5-year bRFS of 82% was
reported. No grade 3 adverse events were noted, and grade 2
toxicities included 3.5% GI and 5.4% GU events. Thus, the
use of PBT alone seemed superior to photon beam RT alone
or photon beam RT combined with PBT17 (Table 1). In addi-
tion, the morbidity rates for prostate cancer have been
evaluated based mainly on grade 2 GI and GU adverse
events since then.
In Japan, three facilities – the National Cancer Center Hospi-
tal East, Shizuoka Cancer Center and Hyogo Ion Beam Medi-
cal Center – carried out a multicenter collaborative phase II
clinical trial of local PBT, delivered at a total dose of 74 GyE/
37 fr to 151 prostate cancer patients between March 2004 and
March 2007. In that trial, no grade 3 adverse events occurred,
and grade 2 late GI and GU toxicities were observed in 2.0%
and 4.1% of patients, respectively.19 Heavy ion RT using car-
bon ions for prostate cancer has been carried out at the National
Institutes of Radiological Sciences in Japan since 1995; the
optimal RT dose and technique were established through two
phase I/II dose-escalation studies of hypofractionated CIRT
carried out there.20 In the phase II trial, which was carried out
between April 2000 and October 2003, a 66 GyE/20 fr dose
fractionation schedule was used based on recommendations
from previous studies, which resulted in grade 2 GI and GU
toxicities in 1.7% and 5.1% of patients, respectively.21
At the beginning of the 21st century, during which the
above results were published, new radiation technologies,
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Fig. 2 Comparison of dose distribution
between volumetric-modulated arc therapy
and PBT. (a) In volumetric-modulated arc ther-
apy using photons, a MLC aperture and dose
rate can be simultaneously adjusted in the
rotational beam of 360° to concentrate the
radiation dose to the prostate. (b) However,
PBT uses fewer beams to create a favorable
dose distribution, thereby minimizing the irra-
diated volumes in the bladder and rectum at
low-to-moderate doses.
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such as IMRT and image-guided brachytherapy, became
widely available as deﬁnitive RT modalities for prostate can-
cer. Furthermore, comparative studies and meta-analyses
showed that ADT improved treatment outcomes, especially
for intermediate- and high-risk prostate cancer, and the ideal
duration and timing of concomitant ADT were deter-
mined.22,23 The treatment outcomes of local high-dose RT
combined with ADT were equal to or superior to those of
local high-dose RT combined with pelvic or prostate RT,
even for high-risk prostate cancer.22–24 Consequently, local
RT combined with effective application of ADT according to
prostate cancer risk stratiﬁcation has become the main treat-
ment for prostate cancer without evidence of metastasis.
Table 2 summarizes the clinical outcomes after IMRT,
PBT and CIRT, along with a comparison of the efﬁcacies
and safety parameters.8,25–38 PBT and CIRT outcomes in
Japanese patients were reported recently in a multicenter col-
laborative clinical study.37,38 Iwata et al. reported long-term
outcomes from a multi-institutional survey of PBT for pros-
tate cancer carried out by the Japanese Radiation Oncology
Study Group. In their study, 1291 patients at seven facilities
received PBT between January 2008 and December 2011,
mainly using the standard fractionation for RT at total doses
ranging from 70 to 80 GyE. After a median follow-up period
of 69 months (range 7–107 months), the 5-year bRFS rates
of the low-, intermediate- and high-risk patients were 97.0%,
91.1% and 83.1%, respectively, and grade 2 GI and GU
adverse events were observed in 4.1% and 4.0% of patients,
respectively.37 In another study, the treatment outcomes of
2157 patients who received CIRT at three facilities between
2003 and 2014 were analyzed.38 Based on the results of clini-
cal studies carried out at the National Institute of Radiologi-
cal Sciences, dose fractionation schedules of CIRT have been
changed from 20 sessions over 5 weeks to 12 sessions over
3 weeks step-by-step.8,21,39 After a median observation period
of 29 months, the 5-year bRFS rates of the low-, intermedi-
ate- and high-risk patients were 92%, 89% and 92%, respec-
tively, and the rates of grade 2 GI and GU adverse events
were 0.4% and 4.6%, respectively.38 Furthermore, Okada
et al.39 showed no signiﬁcant difference in the 5-year bio-
chemically relapse-free rates between 16 and 20 sessions
groups (88.5% and 90.2%, respectively), and the decrease in
the number of CIRT fractions did not increase the incidences
of the late adverse events (Table 3).8,39,40 Thus, particle beam
RT was shown to achieve well-balanced treatment outcomes
in terms of both efﬁcacy and safety.
Comparisons of RT methods in terms of
HRQOL
Recent advances in RT technologies and techniques have
improved the outcomes of prostate cancer. However, it is dif-
ﬁcult to determine the optimal RT method simply by compar-
ing bRFS and/or morbidity rates among individual
treatments. Recently, HRQOL, which is measured using
questionnaires, such as the FACT-P and EPIC, has become
an increasingly important end-point in the evaluation of treat-
ments for localized prostate cancer.41,42
Maruyama et al. reported long-term results of HRQOL
assessments carried out at ﬁve time points (immediately
before and immediately after the initiation of CIRT, and at
12, 36 and 60 months after completion of CIRT) using the
FACT-P questionnaire.43 In their study, the absolute change
in the FACT-P score was minimal, and the transient decrease
observed in the TOI score returned to baseline at 1 year after
CIRT. Their results suggested that the changes in the
HRQOL score observed after CIRT was minimal compared
with the results from a previous report on photon beam RT
Table 1 Clinical outcomes of photon and PBT trials carried out in the 1990s
Author No. patients Period Total dose (Gy) Photon (Gy) Proton (GyE) End-point
Late toxicity
GI GU
WPI and local RT
Shipley14 202 1982–1992 75.6 50.4 (WPI) 25.2 (local) Local control
(8 years)
73% 2.9% (G3)† NA
67.2 50.4 (WPI) + 16.8 (local) – 59% 0% (G3)† NA
Roach15 440 1995–1999 70.2 50.4 (WPI) + 19.8 (local) PFS (7 years) 40% 4.3% (G3) 3.0% (G3)
70.2 70.2 (local) 27% 0% (G3) 0% (G3)
Local RT
Zietman16 393 1996–1999 79.2 50.4 (local) 28.8 (local) bRF (10 years) 83% 24% (G2)
1% (G3)
27% (G2)
2% (G3)
70.2 50.4 (local) 19.8 (local) 67% 13% (G2)
0% (G3)
22% (G2)
2% (G3)
Kuban6 301 1993–1998 78.0 78.0 (local) – FFF (10 years) 73% 26% (G2)
7% (G3)
13% (G2)
5% (G3)
70.0 70.0 (local) – 50% 13% (G2)
1% (G3)
8% (G2)
4% (G3)
Schulte17 911 1991–1996 74–75 – 74.0–75.0 (local) bRF (5 years) 82% 3.5% (G2)
0% (G3)
5.4% (G2)
0% (G3)
†As the details of three patients with grade ≥3 rectal bleeding are unknown, the percentages in the table are based on the assumption that all three received
high-dose RT using protons.
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and brachytherapy (Table 4).43,44 Furthermore, a decrease in
the TOI score was related to use of adjuvant ADT, onset of
adverse events and biochemical recurrence.43 One likely rea-
son why there was little effect on the HRQOL score might
be the lower rates of adverse events and biochemical recur-
rence after CIRT.
Gray et al. compared the bowel/rectal and urinary QOL
after 3DCRT (n = 123), IMRT (n = 153) and PBT
(n = 95).45 During the immediate post-treatment period
(2 months from the start of treatment for the IMRT cohort,
and 3 months from the start of treatment for the 3DCRT and
PBT cohorts), patients in the IMRT, but not the PBT, cohort
reported a clinically meaningful decrease in both bowel/rectal
and urinary (irritation/obstruction and incontinence) QOL. In
contrast, at 12 months, patients who received PBT, but not
those who received IMRT or 3DCRT, reported a clinically
meaningful decrease in urinary irritation/obstruction QOL.45
At the University of Florida (USA), 1243 patients treated
with 76–78 Gy PBT were compared with 204 patients treated
with nearly the same dose of IMRT (75.6–79.4 Gy) in terms
of HRQOL based on the EPIC score. Urinary and sexual
function did not differ during the treatment course when the
Table 2 Comparison of IMRT with particle beam therapy for treatment of prostate cancer
Author Year RT type No. patients Total dose (Gy/GyE) Fractions
5-year bRF/bRFS (%)
Toxicity
(grade 2)
Low-risk Intermediate-risk High-risk GI (%) GU (%)
IMRT
Zelefsky25 2006 X-ray 561 81 45 89 (8 years)† 78 (8 years)† 67 (8 years)† 1.6 15
Kupelian26 2007 X-ray 770 70 28 94† 83† 72† 6 7
Vora27 2007 X-ray 145 70.2–77.4 39–43 88‡ 73‡ 60‡ 24 29
Cahlon28 2008 X-ray 478 86.4 48 98† 85† 70† 4 16
Martin29 2009 X-ray 92 79.8 45 88‡ 77‡ 78‡ 13.7 12.1
Spratt30 2013 X-ray 1002 86.4 48 98 (7 years)† 86 (7 years)† 68 (7 years)† 4.4 21.1
Guckenberger31 2014 X-ray 150 73.9–76.2 32–33 88‡ 80‡ 78‡ 4.7 22.4
Lieng32 2017 X-ray 123 60–66 20–22 100‡ 89‡ 56‡ 7.3 12.2
Takemoto33 2018 X-ray 348 72.8–79 33–39 93 (7 years)‡ 93 (7 years)‡ 80 (7 years)‡ 10.1 6.0
Particle beam therapy
Mendenhall34 2014 Proton 211 78–82 34–41 99‡ 99‡ 76‡ 1.0§ 0.9§
Bryant35 2016 Proton 1327 72–82 36–41 99† 94† 74† 0.6§ 2.9§
Takagi36 2017 Proton 1375 74 37 99† 91† 86† 3.9 2.0
Iwata37 2018 Proton 1291 70–80/63–66 35–40/21–22 97‡ 91‡ 83‡ 4.1 4.0
Ishikawa8 2012 Carbon 927 63–66/57.6 20/16 90† 97† 88† 1.9 6.3
Nomiya38 2016 Carbon 2157 63–66/57.6/51.6 20/16/12 92‡ 89‡ 92‡ 0.4 4.6
†bRF rate. ‡bRFS rate. §Grade 3.
Table 3 Late toxicity according to dose fractionation schedule after carbon-ion therapy
Author
Dose fractionation
(GyE/fr/weeks) No. patients
Median follow-up
time (months)
Rectal toxicity (%) GU toxicity (%)
G0 G1 G2 G3 G0 G1 G2 G3
Ishikawa8 66.0/20/5 250 43.0 78.0 18.8 3.2 0 40.4 46.0 13.6 0
Ishikawa8 63.0/20/5 216 43.0 85.2 12.5 2.3 0 50.0 43.1 6.5 0.5
Okada39 57.6/16/4 198 59.3 88.9 9.6 1.5 0 58.6 39.4 2.0 0
Nomiya40 51.2/12/3 46 32.3 91.3 8.7 0 0 50.0 50.0 0 0
Table 4 TOI scores after different treatments for prostate cancer
Treatment
No.
patients
Median age
(years) Baseline
Time after treatment
1 month 12 months 36 months
Mean TOI score43,44 (change
from baseline)
RP 23 61 88.3  12.3 66.2  10.3 (22.1) 88.2  3.7 (0.1) NA
Brachytherapy 44 67 86.9  6.0 68.6  7.7 (18.3) 85.8  7.3 (1.1) NA
3DCRT 23 69 85.3  9.1 77.6  18.1 (7.7) 84.1  13.7 (1.2) NA
CIRT 417 69 81.8  12.0 77.8  12.1 (4.0) 80.3  13.0 (1.5) 81.6  13.7 (0.2)
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comparisons between cohorts were controlled for age, pros-
tate size, ADT use and baseline QOL, but the frequencies of
“moderate/big problems” with rectal urgency (P = 0.02) and
bowel frequency (P = 0.05) were greater in the IMRT
cohort.46 In fact, Fang et al. assessed the associations
between toxicity and PBT compared with IMRT in prostate
cancer patients using a case-matched analysis; the risks of
late GI and GU toxicities were not different between the two
groups. However, grade ≥2 acute GI toxicities were recorded
in 13 (13.8%) patients treated with IMRT and four (4.3%)
patients treated with PBT, and PBT was signiﬁcantly associ-
ated with a reduced risk of acute GI toxicities in univariate
analysis (P = 0.03).47 Based on these results, the HRQOL
indicators in low- and intermediate-risk patients receiving
PBT or IMRT are currently being compared (PARTIQoL
trial: NCT01617161). That trial is the ﬁrst to compare IMRT
with PBT directly, and evaluation of the primary end-point,
the EPIC mean bowel score at 24 months post-treatment, is
scheduled for completion in December 2019.
To summarize these results, although no comparative study
results are available at the present time, the current National
Comprehensive Cancer Network guidelines on PBT state that,
based on the results of many clinical studies, there is no clini-
cal evidence supporting a beneﬁt or disadvantage of PBT
over IMRT in terms of treatment efﬁcacy or long-term toxici-
ties. The usefulness of PBT has been conﬁrmed, and conven-
tionally fractionated prostate PBT can be considered a
reasonable alternative to X-ray-based regimens at clinics with
the appropriate technology, physics and clinical expertise.
Future prospects
Particle beam RT for prostate cancer in Japan has changed
considerably, and as of April 2018, it is eligible for insur-
ance coverage. Of note, patients can receive particle beam
RT without paying expensive fees, and the cost of this
advanced medical treatment is similar to those of other RTs,
such as IMRT and brachytherapy. The cost–beneﬁt of parti-
cle beam RT was previously considered inferior to that of
photon beam RT, but with development of this treatment
modality, particle beam RT might now provide a potential
cost-effective treatment in Japan.48,49 However, to establish
the routine use of particle beam RT worldwide, it is still
necessary to further reduce the size and cost of the device
for particle beam RT.
Furthermore, recent technological advances have led to
changes in the beam delivery, position veriﬁcation and
radiation techniques of particle beam RT, which will not
only improve treatment outcomes, but also reduce the cost
and treatment time.50–53 In particular, image-guided inten-
sity-modulated particle beam RT using a new beam deliv-
ering method, known as pencil beam scanning, provides
more highly conformal and precise treatments beyond what
were available previously (Fig. 3).50,51 By further decreas-
ing the irradiated volumes and doses in the rectum and
bladder, the incidence of GI and GU toxicities is expected
to decrease.
With an increase in the number of patients treated with parti-
cle beam RT (Fig. 4), creating a system that allows treatment
of more patients while maintaining treatment quality is critical.
To overcome this issue for the future, hypofractionation is a
promising strategy, especially for prostate cancer treatment,
based on radiobiological models.13 In fact, several studies of
hypofractionated particle beam RT for prostate cancer have
been carried out, and reported the same or lower incidences of
adverse events as those seen with conventional photon beam
RT using standard fractionation.8,21,38–40,54 Further conﬁrma-
tion of the feasibility and efﬁcacy of hypofractionated particle
beam RT will enable an increase in patient volume and reduc-
tion in the cost per patient. Currently, the JASTRO is carrying
out a multi-institutional prospective study of hypofractionated
particle beam RT, using PBT for intermediate-risk and CIRT
for high-risk prostate cancer. Furthermore, another multi-insti-
tutional study of IMRT for all prostate cancer risk groups is
currently being carried out. Although the outcomes obtained
from these prospective studies cannot be compared directly,
JASTRO intends to evaluate the efﬁcacies of the various RT
modalities for prostate cancer.
Conclusions
Due to a lack of direct evidence, the superiority of particle
beam RT over photon beam RT for prostate cancer has not
been conﬁrmed in terms of the rates of overall survival or
bRFS as end-points. However, charged particles, such as
(b)(a)
ProtonProton
Second
scatterer
Ridge filter
Bolus
Patient
Binary
range
shifter
collimator
Iso-center
First scatterer
Scanning 
magnet 
Fig. 3 Different beam delivering methods for particle beam therapy. (a) The
passive scattering method for particle beam preparation: after making a
broad beam of charged particles by scatterers, the SOBP is made though the
ridge filter. A binary range shifter changes the beam energy, and the com-
pensation bolus is fabricated for each patient to make the distal configura-
tion of the SOBP similar to the target. (b) The collimator defines the
irradiation field. Pencil beam scanning method. Scanning magnets are used
to three-dimensionally scan narrow beams through the target. The technique
enables intensity-modulated particle therapy to reduce unnecessary doses to
normal tissues compared with the passive scattering method.
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protons and carbon ions, reduce the irradiated volumes and
doses in the organs at risk surrounding the prostate, and pre-
vious studies have shown very low incidences of GI and GU
toxicities after particle beam RT. Here, we reviewed treat-
ment outcomes during different eras of particle beam RT, and
the adverse events induced by particle beam RT have consis-
tently been acceptable. Long-term observation in a large-scale
randomized study is necessary for the most accurate evalua-
tion of the efﬁcacy of particle beam RT for prostate cancer,
but particle beam RT seems a reasonable RT method deliver-
ing a high RT dose safely. During 2015–2017, the JASTRO
committee for particle beam RT discussed this matter. At that
time, particle beam RT was still considered an advanced
medical treatment, and it was expected that patients would
not refuse randomization in clinical trials. Therefore, we are
carrying out a multi-institutional prospective study of IMRT,
PBT and CIRT, and registration of all studies will be com-
pleted by April 2020. Together with the recent increase in
the number of facilities offering particle beam RT in Japan
(Table 5), data on treatment outcomes for various diseases
including prostate cancer have accumulated, and are stored in
a nationwide database. In addition, it is possible that the
treatment devices will become smaller in size and less expen-
sive in the near future. We are facing an important point at
which particle beam RT can be compared directly with not
only IMRT, but also other alternative treatments, such as sur-
gery or brachytherapy, from several points of view, such as
recurrence, adverse events, QOL and cost.
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